Notable data on evofem's solosec in recurrent bacterial vaginosis (bv) released at acog annual meeting

-- bv market projected to reach $1.0 billion in the u.s. by 2033 -- -- bv affects 21 million u.s. women; as many as 50% experience recurrent bv within six months of treatment -- san diego , june 11, 2025 /prnewswire/ -- women's health innovator evofem biosciences, inc. (otcpk: evfm) today announced that a study of solosec® (secnidazole) 2 g oral granules for recurrent bacterial vaginosis (bv) presented at the 2025 american college of obstetricians and gynecologists (acog) annual clinical and scientific meeting supports further development of solosec for the management of recurrent bv, a potential new indication. in a focused clinical study of 24 women with recurrent bv, once-weekly dosing with secnidazole oral granules (solosec) demonstrated efficacy matching or potentially surpassing outcomes of current cdc-recommended suppressive treatments.
BV Ratings Summary
BV Quant Ranking